biostudies-literatureCai CXNICHD NIH HHSNEINEI NIH HHSNCATS NIH HHSNIA NIH HHSNIDDK NIH HHSNHLBI NIH HHSNLM NIH HHS733-743https://www.ebi.ac.uk/biostudies/studies/S-EPMC11298306biostudies-literatureUnknown8(8)<h4>Purpose</h4>To characterize the incidence of kidney failure associated with intravitreal anti-VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab, aflibercept, or bevacizumab.<h4>Design</h4>Retrospective cohort study across 12 databases in the Observational Health Data Sciences and Informatics (OHDSI) network.<h4>Subjects</h4>Subjects aged ≥ 18 years with ≥ 3 monthly intravitreal anti-VEGF medications for a blinding disease (diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, or retinal vein occlusion).<h4>Methods</h4>The standardized incidence proportions and rates of kidney failure while on treatment with anti-VEGF were calculated. For each comparison (e.g., aflibercept versus ranibizumab), patients from eacOphthalmology. RetinaSimilar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study.PMC11298306F30 HL168842R01 AG068002R01 LM006910UL1 TR003098U24 HD113136R01 LM013426K23 EY033440K24 HL148181K23 DK132459K23 EY032985McLeggon JAMatheny MEGoetz KBlacketer CSuchard MABu FDesai PZhang LSwerdel JLee ECai CXShoaibi ANagy PBowring MGLawrence-Archer LBoland MVCrews DCNg JHGilbert ZFalconer THall NOstropolets ATran DDuVall SLNishimura AGolozar AWestlund EMinty ECook MReps JToy BZeger SLSena AGJhaveri KDHripcsak GHribar MRyan PBfalseSimilar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study.<h4>Purpose</h4>To characterize the incidence of kidney failure associated with intravitreal anti-VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab, aflibercept, or bevacizumab.<h4>Design</h4>Retrospective cohort study across 12 databases in the Observational Health Data Sciences and Informatics (OHDSI) network.<h4>Subjects</h4>Subjects aged ≥ 18 years with ≥ 3 monthly intravitreal anti-VEGF medications for a blinding disease (diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, or retinal vein occlusion).<h4>Methods</h4>The standardized incidence proportions and rates of kidney failure while on treatment with anti-VEGF were calculated. For each comparison (e.g., aflibercept versus ranibizumab), patients from eac2024-01-01T00:00:00Z2024 Aug2026-03-17T15:31:07.832Z2025-08-16T03:06:58.908ZS-EPMC112983063851902610.1016/j.oret.2024.03.014